Sun Pharma eyes global expansion with USD 11.75 bn Organon deal

In a move that signals India’s growing ambition in the global pharmaceutical space, Sun Pharmaceutical Industries Ltd has announced one of its biggest overseas acquisitions, a massive $11.75 billion all-cash deal to acquire US-based Organon & Co . More than just a business transaction, this deal reflects a strategic push to position an Indian company among the world’s top pharma giants.

Under the agreement, Sun Pharma will acquire all outstanding shares of Organon at $14 per share , marking a significant milestone not only for the company but for India Inc. globally. Once completed, the combined entity is expected to generate revenues of around $12.4 billion , placing Sun Pharma among the top 25 pharmaceutical companies worldwide .

Organon, carved out of Merck (MSD) in 2021, brings with it a strong global footprint — operations in over 140 countries , six manufacturing facilities, and a diverse portfolio of 70+ products , especially in women’s health and biosimilars . This is where the deal becomes strategically sharp. Sun Pharma is set to emerge as a top-three player in global women’s health and the seventh-largest biosimilar company worldwide.

Executive Chairman Dilip Shanghvi described the acquisition as a step toward expanding the company’s vision of “reaching people and touching lives,” emphasizing how Organon’s capabilities complement Sun Pharma’s existing strengths. On the other side, Organon’s leadership called the deal a move that delivers immediate value to shareholders while ensuring long-term growth under Sun Pharma’s umbrella.

Beyond scale, the numbers reveal deeper intent. The combined business expects to unlock over $350 million in synergies within 2-4 years , backed by a presence in 150 countries and at least 18 major markets each generating over $100 million in revenue.

This acquisition now joins the ranks of landmark Indian global deals, such as Tata Steel’s Corus takeover and Bharti Airtel’s acquisition of Zain’s African business, reinforcing a pattern of Indian firms expanding aggressively beyond borders.

However, the road ahead isn’t without challenges. The deal, expected to close by early 2027, still awaits regulatory approvals and shareholder consent , and Organon’s existing debt of $8.6 billion will need careful management.

Yet, if executed well, this could redefine Sun Pharma’s global identity, not just as India’s largest drugmaker, but as a truly global healthcare powerhouse .